The Future of Medicine

Kelly: Will this benefit big money incumbents or startup Mavric E Biotex more? Michael: I think it's both. Bristol Myers, Amgen and Moderna are in the early stages of trying to determine using patient data how a computer could identify which genes are going to be the best to go after. Even some public companies like Schrodinger, which we mentioned, is partially 10% owned by the Bill Gates Foundation; other private companies that are trying to look at this with data as well. Kelly: In 10 years, let's see how fast technology develops.